AAA
BBOT

Affinity Asset Advisors’s BridgeBio Oncology BBOT Stock Holding History

Affinity Asset Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250,000
Closed -$2.63M – 113
2024
Q4 		$2.63M Hold
250,000
– – 0.35% 54
2024
Q3 		$2.61M Hold
250,000
– – 0.36% 60
2024
Q2 		$2.56M Hold
250,000
– – 0.29% 61
2024
Q1 		$2.59M Buy
+250,000
New +$2.59M 0.32% 69

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return

Affinity Asset Advisors's BBOT Position: Q1 2025 in Review

Affinity Asset Advisors sold out of BridgeBio Oncology (BBOT) in Q1 2025, closing a stake of 250,000 shares — an estimated $2.63M sold.

Affinity Asset Advisors first reported a position in BBOT in Q1 2024 and held it in 4 quarters. The position peaked at $2.63M in Q4 2024. 31 funds tracked by Wall St. Rank hold BBOT as of Q1 2025.

  • Affinity Asset Advisors reported no remaining BridgeBio Oncology position as of Q1 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 250,000 BridgeBio Oncology shares in Q1 2025, an estimated $2.63M.
  • Affinity Asset Advisors first reported a position in BridgeBio Oncology in Q1 2024 and held it in 4 quarters.
  • Affinity Asset Advisors's BridgeBio Oncology position peaked at $2.63M in Q4 2024.
  • 31 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2025.

Based on Affinity Asset Advisors's 13F filing for Q1 2025, filed 14 May 2025.